Quest Diagnostics Incorporated (DGX) to Issue Quarterly Dividend of $0.86 on July 22nd

Quest Diagnostics Incorporated (NYSE:DGXGet Free Report) announced a quarterly dividend on Tuesday, May 19th. Investors of record on Wednesday, July 8th will be paid a dividend of 0.86 per share by the medical research company on Wednesday, July 22nd. This represents a c) dividend on an annualized basis and a yield of 1.6%. The ex-dividend date of this dividend is Wednesday, July 8th.

Quest Diagnostics has increased its dividend by an average of 0.1%per year over the last three years and has raised its dividend every year for the last 14 years. Quest Diagnostics has a dividend payout ratio of 32.7% meaning its dividend is sufficiently covered by earnings. Research analysts expect Quest Diagnostics to earn $11.56 per share next year, which means the company should continue to be able to cover its $3.44 annual dividend with an expected future payout ratio of 29.8%.

Quest Diagnostics Stock Down 0.2%

NYSE:DGX opened at $215.35 on Monday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.18 and a quick ratio of 1.08. Quest Diagnostics has a 1-year low of $164.65 and a 1-year high of $217.41. The company has a 50-day moving average of $197.41 and a 200 day moving average of $194.02. The firm has a market cap of $23.84 billion, a PE ratio of 23.80, a price-to-earnings-growth ratio of 2.57 and a beta of 0.58.

Quest Diagnostics (NYSE:DGXGet Free Report) last announced its earnings results on Tuesday, April 21st. The medical research company reported $2.50 earnings per share for the quarter, beating the consensus estimate of $2.37 by $0.13. Quest Diagnostics had a net margin of 9.07% and a return on equity of 15.60%. The company had revenue of $2.90 billion during the quarter, compared to the consensus estimate of $2.83 billion. During the same period last year, the firm earned $1.94 earnings per share. Quest Diagnostics’s revenue was up 9.2% compared to the same quarter last year. Quest Diagnostics has set its FY 2026 guidance at 10.630-10.830 EPS. As a group, research analysts anticipate that Quest Diagnostics will post 10.72 EPS for the current fiscal year.

About Quest Diagnostics

(Get Free Report)

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.

Read More

Dividend History for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.